Microvascular health analysis. In a blood sample.
Our mission
To enable breakthroughs in predictive and preventative medicine by making microvascular health and disease routinely detectable for patients, doctors and scientists.
The health of the body’s microvascular systems - networks of tiny blood vessels that supply organs with a constant supply of oxygen and nutrients - is fundamental to the health of every organ in the body. Damage to these networks (microvascular disease) leads to organ dysfunction and life-threatening disease. But observing changes in these tiny blood vessels buried deep within the body is extremely difficult, and currently requires complex and expensive medical imaging technologies.
At Dimension Biotechnologies, we want to equip doctors, drug developers and scientists with the tools to routinely assess microvascular health and disease in hospitals and research labs around the world. In doing so, we can enable breakthroughs in predictive and preventative medicine in diverse areas of human health from heart disease to kidney disease, diabetes and critical illness.
Our science
The endothelial glycocalyx
The endothelial glycocalyx is a dynamic, sugar-rich layer that lines the inner surface of all blood vessels in the body, serving as the primary interface between circulating blood and the vessel wall. This structure regulates molecular transport between blood and tissues and is crucial for microvascular function.
Biochemical alterations of the endothelial glycocalyx occur early in many different diseases, including cardiovascular disease, kidney disease, diabetes, and sepsis, making it a valuable biomarker for evaluating microvascular health and disease.
Our technology enables routine glycocalyx analysis
Analysing endothelial glycocalyx biochemistry currently requires invasive tissue biopsies and high-resolution microscopy. This lack of effective and usable tools for glycocalyx analysis is preventing its utility as a biomarker for assessing microvascular health and disease in both the clinic and scientific research.
Through world-leading research led by the Bristol Renal laboratory at University of Bristol Medical School, we have developed a rapid and robust method of analysing glycocalyx biochemistry using newly identified biomarker signatures in a blood sample.
We now plan to deploy this technology as a liquid biopsy for microvascular health and disease, enabling scientists to routinely assess endothelial glycocalyx in basic research & drug development, and enabling doctors to routinely evaluate glycocalyx health as a prognostic marker in the clinic.
Our advantages
Biochemical readout
Analyses glycocalyx changes at the biochemical level.
Rapid
Readout in minutes
Easy to adopt
Compatible with existing spectroscopy equipment
If you’re interested in piloting our technology, or simply want to learn more about the microvascular insights we can provide, we want to speak to you.
About us
Founded in 2025, we are a spinout from the Bristol Renal research group in the University of Bristol Medical School. Our founding team combines the expertise of these world-leading microvascular and glycocalyx researchers with experienced spinout operators and biosensor development specialists. We are based within the Science Creates ecosystem in central Bristol.
